GlassScriptPhysician profile
Hollie A Yoder
NPI 1548476922
$2,638.77
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.15 · 2022: $75.98 · 2023: $898 · 2024: $1,135 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $494.27 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $417.18 | 2023-2025 | |
| Novo Nordisk INC | $379.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $244.38 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Neurocrine Biosciences, INC. | $126.23 | 2023 | Ongentys |
| Glaxosmithkline, LLC. | $125.82 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $97.66 | 2022-2025 | |
| Amgen INC. | $96.24 | 2023-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $91.19 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $84.80 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.04 | 2023-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $54.14 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $49.83 | 2025 | |
| Xeris Pharmaceuticals, INC. | $46.38 | 2023-2024 | Gvoke Hypopen |
| Abbott Laboratories | $45.74 | 2024 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.84 | 2023 | |
| Axsome Therapeutics, INC. | $30.81 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $27.38 | 2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $19.85 | 2022 | |
| Sumitomo Pharma America, INC. | $17.99 | 2023 | Gemtesa |
| Hikma Pharmaceuticals USA | $16.31 | 2023 | Mitigare, Ryaltris |
| Nestle Healthcare Nutrition INC. | $15.43 | 2022 | |
| Phadia US INC. | $14.24 | 2023 | Immunocap |
| Amarin Pharma, INC. | $14.05 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hollie Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.